Paclitaxel by 3-H infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the hellenic cooperative oncology group
- 1 October 1997
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (11) , 1893-1895
- https://doi.org/10.1016/s0959-8049(97)00217-7
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A phase II study of paclitaxel in platinum pretreated ovarian cancer. A hellenic cooperative oncology group studyEuropean Journal Of Cancer, 1997
- A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclinesEuropean Journal Of Cancer, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Paclitaxel in Metastatic Breast Cancer:-a Trial of Two Doses by a 3-Hour Infusion in Patients With Dith Disease Recurrence After Prior Therapy With AnthracyclinesJNCI Journal of the National Cancer Institute, 1995
- Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.Journal of Clinical Oncology, 1995
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.Journal of Clinical Oncology, 1994
- Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule.Journal of Clinical Oncology, 1993
- Reporting results of cancer treatmentCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958